| 单克隆抗体治疗卵巢癌的研究进展 |
| |
| 引用本文： | 张淼苗（综述）,喇端端（审校）. 单克隆抗体治疗卵巢癌的研究进展[J]. 国外医学:妇产科学分册, 2010, 37(2): 129-131,141 |
| |
| 作者姓名： | 张淼苗（综述） 喇端端（审校） |
| |
| 作者单位： | 上海交通大学医学院附属瑞金医院妇产科,200025 |
| |
| 摘 要： | 单克隆抗体治疗卵巢癌的实验与临床研究均已取得较大进展。贝伐单抗（nevacizumab,BEV）通过抑制新生血管形成,达到抑制肿瘤的目的;曲妥珠单抗（trastuzumab）、帕妥珠单抗（pertuzumab）选择性作用于人类表皮生长因子受体2,抑制肿瘤细胞的生长;西妥昔单抗（cetuximab）通过结合细胞表皮生长因子受体1,抑制细胞增殖、诱导凋亡;oregovomab通过与CA125形成免疫复合物,引起针对CA125的独特型免疫应答。单克隆抗体治疗卵巢癌可弥补传统治疗的不足。综述单克隆抗体治疗卵巢癌的研究进展。
|
| 关 键 词： | 卵巢癌 单克隆抗体 治疗 |
Monoclonal Antibodies in Ovarian Cancer |
| |
| Affiliation: | ZHANG Miao-miao,LA Duan-duan.Department of Obsterics and Gynecology,Ruijin Hospital,Affiliated to Shanghai Jiaotong University,Shanghai 200025,China |
| |
| Abstract: | The use of monoclonal antibodies for treating ovarian cancer has been gaining interest and has already made impressive progress in both the pre -clinical and clinical trials.Bevacizumab inhibits tumor growth through anti-angiogenesis Trastuzumab and pertuzumab inhibit tumor growth after binding with HER2.Cetuximab enhances cell apoptosis and interferes with cancer cell proliferation after binding with EGFR1.Oregovomab binds to CA125,forming complexes that cause a specific immune response to CA125.Targeted treatment with monoclonal antibodies can make up for the deficiency of traditional treatment.This paper reviews the recent achievements in the development of monoclonal antibodies for treating ovarian cancer. |
| |
| Keywords: | Ovarian cancer Monoclonal antibodies Treatment |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
